Colorado 2025 Regular Session

Colorado House Bill HB1316

Introduced
4/1/25  
Refer
4/1/25  
Report Pass
4/8/25  
Refer
4/8/25  
Engrossed
4/22/25  
Refer
4/22/25  
Report Pass
4/30/25  
Refer
4/30/25  
Engrossed
5/20/25  
Engrossed
5/20/25  
Enrolled
5/20/25  

Caption

Changes to Definitions Monitoring of Prescription Drugs

Summary

HB25-1316 makes a narrow, technical update to the definitions used in Colorado’s laws governing electronic monitoring of prescription drugs. The bill repeals the existing definition of “drug abuse” and replaces it with a definition of “substance use disorder,” describing it as a chronic relapsing brain disease involving recurrent use of alcohol or drugs that causes clinically significant impairment, including health problems, disability, and failure to meet major responsibilities at work, school, or home. The measure appears aimed at aligning statutory terminology with more current clinical language and public health framing. It does not create a new monitoring program or expand enforcement authority; instead, it updates the definitions section of the prescription drug monitoring laws so that related provisions use terminology that reflects substance use disorder rather than the older “drug abuse” phrasing.

Impact

The bill amends Colorado Revised Statutes section 12-280-402, which supplies definitions for the state’s prescription drug monitoring framework. By repealing the prior “drug abuse” definition and adding a “substance use disorder” definition, it changes the statutory language that may be referenced in administering or interpreting the laws regulating electronic monitoring of prescription drugs. The practical effect is limited to terminology and definitional alignment, with no apparent change to penalties, reporting duties, or program structure.

Sentiment

The bill appears to have been broadly noncontroversial and received strong support in both chambers. It passed the House Health & Human Services Committee unanimously, cleared House third reading with a substantial majority, and then passed the Senate Health & Human Services Committee and Senate third reading without any recorded opposition. The committee recommendation to place it on the consent calendar further suggests general agreement that the bill was technical and routine rather than substantive.

Contention

There is little evidence of significant contention in the available record. The only potentially sensitive issue is the shift from the older term “drug abuse” to “substance use disorder,” which reflects a more clinical and less stigmatizing approach to addiction-related terminology. However, the unanimous committee votes and lack of recorded debate indicate that any disagreement, if present, was minimal and did not affect the bill’s progress.

Companion Bills

No companion bills found.

Similar Bills

No similar bills found.